CLINICAL_TRIALS ClinicalTrials.gov record update

INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07686757
Title field or adapter rule: {'original_value': 'INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:36.001017+00:00
Published At: 2026-10-29T00:00:00+00:00
Record Updated At: 2026-10-29
Source Retrieved At: 2026-10-31T22:18:58.295941+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Ulcerative Colitis (UC)", "Crohn Disease (CD)"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07686757"
protocolSection.identificationModule.officialTitle: "INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab"
protocolSection.statusModule.overallStatus: "ENROLLING_BY_INVITATION"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Mirikizumab Clinical Care Pathway'], 'description': "Mirikizumab administered according to approved dosing regimens for ulcerative colitis and Crohn's disease.", 'name': 'Mirikizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Standard Biologic Therapy Clinical Care Pathway'], 'description': 'Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.', 'name': 'Anti-TNF agents', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Standard Biologic Therapy Clinical Care Pathway'], 'description': 'Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.', 'name': 'anti-integrin antibodies', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Standard Biologic Therapy Clinical Care Pathway'], 'description': 'Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.', 'name': 'IL-12', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Standard Biologic Therapy Clinical Care Pathway'], 'description': 'Biologic therapies administered per routine clinical care, including anti-TNF agents, anti-integrins, IL-12/23 antagonists, and IL-23p19 antagonists.', 'name': 'IL-23', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.